Clinical Trial Update: CART22 Alone or in Combination With huCART19 for ALL [Phase 1]

View source ↗

Summary

A Phase 1 study at University of Pennsylvania evaluating CART22 alone or in combination with huCART19 for chemotherapy-resistant or refractory acute lymphoblast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• CART22
• huCART19

Snippet

Sponsor: University of Pennsylvania | Conditions: Chemotherapy Resistant Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING